brand.gif

CCSB Seminar: Mining Synthetic Lethals from Primary Tumor Genomes: Applications to Precision Cancer Therapy

Apr 27, 2018 (Fri) | 12:30 PM -1:30 PM
Clark Center - S360 : Stanford, CA

Abstract: Synthetic lethality refers to a genetic interaction where single gene defects are compatible with cell viability, but combinations result in cell death. The synthetic lethality paradigm provides a new approach to find targeted therapies for cancers with “undruggable” mutations – using inhibitors of the synthetic lethal (SL) partners of cancer mutations to selectively kill cancer cells. An example of a synthetic lethality-based therapy to reach the clinic is the targeting of BRCA1- and BRCA2-deficient tumor cells with PARP inhibitors. Today, there is increased interest in identifying SL partners of other cancer mutations in the hope of discovering new therapeutic options for untreatable cancers...
Refreshments will be provided

Department:  Radiology

Contact: Ramzi Totah | 6507214161 | rtotah@stanford.edu

Presenter(s):